Promis Neurosciences (PMN) Financials

Promis Neurosciences logo
$3.16 -0.05 (-1.56%)
Closing price 11/20/2026 04:00 PM Eastern
Extended Trading
$2.94 -0.22 (-6.96%)
As of 11/20/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Annual Income Statements for Promis Neurosciences

Annual Income Statements for Promis Neurosciences

This table shows Promis Neurosciences' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2021 2022 2023 2024 2025
Period end date 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders
-9.79 -18 -13 2.78 -40
Consolidated Net Income / (Loss)
-9.79 -18 -13 2.78 -40
Net Income / (Loss) Continuing Operations
-9.79 -18 -13 2.78 -40
Total Pre-Tax Income
-9.79 -18 -14 2.78 -40
Total Operating Income
-8.29 -23 -14 -17 -40
Total Gross Profit
0.00 0.00 0.00 0.00 0.00
Total Revenue
0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue
0.00 0.00 0.00 0.00 0.00
Total Operating Expenses
8.29 23 14 17 40
Selling, General & Admin Expense
3.66 7.29 6.38 6.19 6.79
Research & Development Expense
4.63 16 7.88 11 33
Total Other Income / (Expense), net
-1.50 5.32 0.67 20 0.45
Interest Expense
0.42 0.28 0.20 0.08 0.00
Other Income / (Expense), net
-1.08 5.60 0.87 20 0.44
Basic Earnings per Share
($1.69) ($2.41) ($1.07) $2.68 ($22.61)
Weighted Average Basic Shares Outstanding
5.79M 7.50M 12.29M 1.04M 1.76M
Diluted Earnings per Share
($1.69) ($2.41) ($1.07) $2.63 ($22.61)
Weighted Average Diluted Shares Outstanding
5.79M 7.50M 12.29M 1.06M 1.76M
Weighted Average Basic & Diluted Shares Outstanding
- 8.58M 18.96M 32.69M 8.97M

Quarterly Income Statements for Promis Neurosciences

This table shows Promis Neurosciences' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Total Costs & Expenses
- - - - - 10 12 - - 12 8.62
Net Income / (Loss) Attributable to Common Shareholders
-3.64 -2.62 9.28 -0.24 -7.35 -10 -12 -11 -8.24 -12 -8.16
Consolidated Net Income / (Loss)
-3.64 -2.62 9.28 -0.24 -7.35 -10 -12 -11 -8.24 -12 -8.16
Net Income / (Loss) Continuing Operations
-3.64 -2.62 9.28 -0.24 -7.35 -10 -12 -11 -8.24 -12 -8.16
Total Pre-Tax Income
-3.64 -2.62 9.28 -0.24 -7.35 -10 -12 -11 -8.24 -12 -8.16
Total Operating Income
-3.68 -2.71 -4.43 -6.00 -7.46 -10 -12 -11 -8.64 -12 -8.62
Total Gross Profit
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Revenue
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Cost of Revenue
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Operating Expenses
3.68 2.71 4.43 6.00 7.46 10 12 11 8.64 12 8.62
Selling, General & Admin Expense
1.55 1.09 1.87 1.68 2.00 1.43 1.95 1.40 1.67 2.74 1.91
Research & Development Expense
2.12 1.63 2.56 4.32 5.46 8.75 9.80 9.37 6.97 9.52 6.71
Total Other Income / (Expense), net
0.04 0.09 14 5.76 0.11 0.07 0.17 0.10 0.40 0.54 0.45
Other Income / (Expense), net
0.12 0.09 14 5.76 0.11 0.07 0.17 0.09 0.40 0.54 0.45
Basic Earnings per Share
($0.19) ($0.13) $0.31 ($0.23) ($5.27) ($7.26) ($5.93) ($6.08) ($1.26) ($1.28) ($0.89)
Weighted Average Basic Shares Outstanding
19.53M 19.77M 30.02M 1.04M 1.39M 1.39M 1.95M 1.76M 6.53M 9.14M 9.14M
Diluted Earnings per Share
($0.19) ($0.13) $0.31 ($0.23) ($5.27) ($7.26) ($5.93) ($6.08) ($1.26) ($1.28) ($0.89)
Weighted Average Diluted Shares Outstanding
19.53M 19.77M 30.07M 1.06M 1.39M 1.39M 1.95M 1.76M 6.53M 9.14M 9.14M
Weighted Average Basic & Diluted Shares Outstanding
18.96M 29.89M 32.69M 32.69M 32.69M 51.81M 53.81M 8.97M 8.97M 8.97M 9.00M

Annual Cash Flow Statements for Promis Neurosciences

This table details how cash moves in and out of Promis Neurosciences' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2021 2022 2023 2024 2025
Period end date 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents
16 -11 6.72 0.69 -7.17
Net Cash From Operating Activities
-9.31 -17 -11 -27 -28
Net Cash From Continuing Operating Activities
-9.31 -17 -11 -27 -28
Net Income / (Loss) Continuing Operations
-9.79 -18 -13 2.78 -40
Consolidated Net Income / (Loss)
-9.79 -18 -13 2.78 -40
Non-Cash Adjustments To Reconcile Net Income
-0.30 -2.08 0.27 4.35 0.86
Changes in Operating Assets and Liabilities, net
0.37 2.85 2.08 -34 11
Net Cash From Investing Activities
0.09 -0.00 -0.00 -0.00 -0.00
Net Cash From Continuing Investing Activities
0.09 -0.00 -0.00 -0.00 -0.00
Purchase of Investments
-0.03 -0.03 -0.03 -0.03 -0.03
Sale and/or Maturity of Investments
0.03 0.03 0.03 0.03 0.03
Net Cash From Financing Activities
26 6.49 18 28 21
Net Cash From Continuing Financing Activities
26 6.49 18 28 21
Issuance of Debt
6.92 - - 0.00 0.70
Issuance of Common Equity
19 6.49 18 28 20
Other Financing Activities, net
- 0.00 0.00 0.03 0.00
Cash Interest Paid
0.00 0.09 0.20 0.08 0.00

Quarterly Cash Flow Statements for Promis Neurosciences

This table details how cash moves in and out of Promis Neurosciences' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Change in Cash & Equivalents
-10 -1.50 21 -8.25 -4.93 -3.85 11 -9.28 58 -10 -9.36
Net Cash From Operating Activities
-10 -1.50 -6.67 -8.72 -4.93 -3.85 -10 -9.28 -12 -10 -9.38
Net Cash From Continuing Operating Activities
-10 -1.50 -6.67 -8.72 -4.93 -3.85 -10 -9.28 -12 -10 -9.38
Net Income / (Loss) Continuing Operations
-3.64 -2.62 9.28 -0.24 -7.35 -10 -12 -11 -8.24 -12 -8.16
Consolidated Net Income / (Loss)
-3.64 -2.62 9.28 -0.24 -7.35 -10 -12 -11 -8.24 -12 -8.16
Non-Cash Adjustments To Reconcile Net Income
0.08 -0.04 3.66 0.65 0.25 0.21 0.20 0.20 0.19 0.41 0.48
Changes in Operating Assets and Liabilities, net
-6.73 1.16 -20 -9.13 2.18 6.05 1.33 1.19 -4.33 0.94 -1.70
Net Cash From Financing Activities
0.19 - 27 0.47 0.00 - 21 -0.00 70 - 0.02
Net Cash From Continuing Financing Activities
0.19 - 27 0.47 0.00 - 21 -0.00 70 - 0.02
Issuance of Common Equity
0.19 - 27 0.47 0.00 - 20 -0.00 70 - 0.02

Annual Balance Sheets for Promis Neurosciences

This table presents Promis Neurosciences' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2021 2022 2023 2024 2025
Period end date 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets
18 6.92 14 19 9.18
Total Current Assets
18 6.90 14 19 9.18
Cash & Equivalents
17 5.88 13 13 6.12
Short-Term Investments
0.03 0.03 0.03 0.03 0.03
Prepaid Expenses
0.74 1.00 0.99 5.59 3.03
Plant, Property, & Equipment, net
0.00 0.00 0.00 0.00 0.00
Total Noncurrent Assets
0.03 0.02 0.00 0.00 0.00
Total Liabilities & Shareholders' Equity
18 6.92 14 19 9.18
Total Liabilities
12 8.27 9.87 2.42 10
Total Current Liabilities
0.93 6.41 9.35 2.22 10
Accounts Payable
0.41 2.98 7.84 1.74 2.54
Accrued Expenses
0.52 3.44 1.51 0.48 7.87
Total Noncurrent Liabilities
11 1.86 0.52 0.20 0.03
Noncurrent Employee Benefit Liabilities
- 0.00 0.42 0.20 0.03
Total Equity & Noncontrolling Interests
5.66 -1.35 3.75 16 -1.26
Total Preferred & Common Equity
5.66 -1.35 3.75 16 -1.26
Total Common Equity
5.66 -1.35 3.75 16 -1.26
Common Stock
68 79 98 108 130
Retained Earnings
-62 -80 -93 -91 -130
Accumulated Other Comprehensive Income / (Loss)
-0.19 -0.20 -0.37 -0.37 -0.37

Quarterly Balance Sheets for Promis Neurosciences

This table presents Promis Neurosciences' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026 9/30/2026
Total Assets
3.55 1.41 25 14 9.51 21 67 57 47
Total Current Assets
3.55 1.41 25 14 9.51 21 66 57 47
Cash & Equivalents
2.50 0.99 22 8.36 4.51 15 64 53 44
Short-Term Investments
0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03
Prepaid Expenses
1.02 0.38 2.94 5.25 4.97 6.03 1.76 3.23 3.05
Plant, Property, & Equipment, net
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Noncurrent Assets
0.00 0.00 0.00 0.00 0.00 0.00 1.80 0.00 0.00
Total Liabilities & Shareholders' Equity
3.55 1.41 25 14 9.51 21 67 57 47
Total Liabilities
3.47 3.69 17 4.17 9.89 12 6.69 7.29 5.40
Total Current Liabilities
2.65 3.17 2.64 4.06 9.82 12 6.61 7.22 5.34
Accounts Payable
1.40 2.02 1.58 1.20 2.78 4.21 1.72 1.79 0.49
Accrued Expenses
1.24 1.16 1.06 2.86 7.04 8.00 4.90 5.42 4.86
Total Noncurrent Liabilities
0.83 0.51 15 0.12 0.07 0.06 0.08 0.08 0.06
Noncurrent Employee Benefit Liabilities
0.72 0.47 0.34 0.11 0.06 0.05 0.08 0.08 0.06
Total Equity & Noncontrolling Interests
0.08 -2.28 7.27 9.47 -0.38 9.19 61 49 42
Total Preferred & Common Equity
0.08 -2.28 7.27 9.47 -0.38 9.19 61 49 42
Total Common Equity
0.08 -2.28 7.27 9.47 -0.38 9.19 61 49 42
Common Stock
98 98 98 108 108 129 200 200 201
Retained Earnings
-97 -100 -90 -98 -108 -120 -139 -150 -159
Accumulated Other Comprehensive Income / (Loss)
-0.37 -0.37 -0.37 -0.37 -0.37 -0.37 -0.37 -0.37 -0.37

Annual Metrics And Ratios for Promis Neurosciences

This table displays calculated financial ratios and metrics derived from Promis Neurosciences' official financial filings.

Metric 2021 2022 2023 2024 2025
Period end date 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding
0.00 8,579,284.00 8,579,284.00 32,689,190.00 53,811,110.00
DEI Adjusted Shares Outstanding
0.00 343,171.00 343,171.00 1,307,568.00 2,152,444.00
DEI Earnings Per Adjusted Shares Outstanding
0.00 -52.63 -38.50 2.13 -18.45
Growth Metrics
- - - - -
Revenue Growth
0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth
0.00% -95.57% 23.69% 121.35% -1,491.09%
EBIT Growth
0.00% -89.68% 24.66% 121.32% -1,491.09%
NOPAT Growth
0.00% -181.99% 39.00% -68.55% -67.09%
Net Income Growth
0.00% -84.50% 26.85% 121.03% -1,529.33%
EPS Growth
0.00% -42.60% 55.60% 121.03% -959.70%
Operating Cash Flow Growth
0.00% -83.05% 36.34% -150.67% -3.45%
Free Cash Flow Firm Growth
0.00% 0.00% 49.39% -245.27% 39.23%
Invested Capital Growth
0.00% 2.11% -22.37% 135.64% -334.17%
Revenue Q/Q Growth
0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth
0.00% 0.00% 20.06% 441.44% -35.66%
EBIT Q/Q Growth
0.00% 0.00% 19.93% 441.44% -35.66%
NOPAT Q/Q Growth
0.00% 0.00% 24.58% -63.54% -13.47%
Net Income Q/Q Growth
0.00% 0.00% 21.81% 593.28% -35.64%
EPS Q/Q Growth
0.00% 0.00% 44.56% 593.28% -3,546.77%
Operating Cash Flow Q/Q Growth
0.00% -3.07% 6.83% -22.30% -2.06%
Free Cash Flow Firm Q/Q Growth
0.00% 0.00% 0.00% -820.59% 46.56%
Invested Capital Q/Q Growth
0.00% 0.00% 0.00% 122.13% -18.64%
Profitability Metrics
- - - - -
Gross Margin
0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin
0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin
0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin
0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin
0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent
100.00% 100.00% 97.17% 100.00% 99.99%
Interest Burden Percent
104.44% 101.59% 101.50% 97.31% 100.00%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)
-172.97% -837.71% -1,098.51% 27.46% -521.61%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% 0.00% -912.42% 0.00%
Operating Return on Assets (OROA)
0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)
0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)
-172.97% -837.71% -1,098.51% 27.46% -521.61%
Return on Equity Simple (ROE_SIMPLE)
-172.97% 1,340.16% -352.02% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
-5.80 -16 -9.98 -17 -28
NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)
-30.50% -17.88% -34.83% 151.08% -119.15%
Return On Investment Capital (ROIC_SIMPLE)
- - -266.00% -102.06% 2,234.01%
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue
0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)
-9.37 -18 -13 2.86 -40
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-8.96 -18 -13 2.86 -40
Valuation Ratios
- - - - -
Price to Book Value (P/BV)
0.00 0.00 2.63 1.88 0.00
Price to Tangible Book Value (P/TBV)
0.00 0.00 2.63 1.88 0.00
Price to Revenue (P/Rev)
0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)
0.00 0.00 0.00 11.15 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 8.97% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00 5.58 0.00
Enterprise Value to Revenue (EV/Rev)
0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 6.18 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 6.18 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - -
Debt to Equity
0.69 0.00 0.00 0.00 0.00
Long-Term Debt to Equity
0.69 0.00 0.00 0.00 0.00
Financial Leverage
-2.31 -4.40 -7.71 -1.28 -1.28
Leverage Ratio
3.14 5.72 8.54 1.61 1.84
Compound Leverage Factor
3.27 5.81 8.67 1.56 1.84
Debt to Total Capital
40.83% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
40.83% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
59.17% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA
-0.44 0.00 0.00 0.00 0.00
Net Debt to EBITDA
1.46 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA
-0.44 0.00 0.00 0.00 0.00
Debt to NOPAT
-0.67 0.00 0.00 0.00 0.00
Net Debt to NOPAT
2.25 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT
-0.67 0.00 0.00 0.00 0.00
Altman Z-Score
0.00 -21.91 -11.88 2.52 -33.48
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - -
Current Ratio
19.07 1.08 1.46 8.52 0.88
Quick Ratio
18.27 0.92 1.35 6.01 0.59
Cash Flow Metrics
- - - - -
Free Cash Flow to Firm (FCFF)
0.00 -17 -8.36 -29 -18
Operating Cash Flow to CapEx
0.00% -859,862.85% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense
0.00 -58.58 -41.52 -376.02 0.00
Operating Cash Flow to Interest Expense
-22.35 -60.39 -53.84 -354.05 0.00
Operating Cash Flow Less CapEx to Interest Expense
-22.13 -60.40 -53.84 -354.05 0.00
Efficiency Ratios
- - - - -
Asset Turnover
0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover
0.00 0.00 0.00 0.00 0.00
Inventory Turnover
0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)
0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)
0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics
- - - - -
Invested Capital
-7.41 -7.25 -8.88 3.16 -7.41
Invested Capital Turnover
0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital
0.00 0.16 -1.62 12 -11
Enterprise Value (EV)
0.00 31 -2.76 18 8.54
Market Capitalization
0.00 37 9.87 31 15
Book Value per Share
$0.98 ($0.16) $0.44 $0.50 ($0.02)
Tangible Book Value per Share
$0.97 ($0.16) $0.44 $0.50 ($0.02)
Total Capital
9.57 -1.35 3.75 16 -1.26
Total Debt
3.91 0.00 0.00 0.00 0.00
Total Long-Term Debt
3.91 0.00 0.00 0.00 0.00
Net Debt
-13 -5.91 -13 -13 -6.15
Capital Expenditures (CapEx)
-0.09 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-0.19 -5.42 -8.36 3.37 -7.38
Debt-free Net Working Capital (DFNWC)
17 0.49 4.27 17 -1.23
Net Working Capital (NWC)
17 0.49 4.27 17 -1.23
Net Nonoperating Expense (NNE)
3.99 1.70 3.23 -20 12
Net Nonoperating Obligations (NNO)
-13 -5.91 -13 -13 -6.15
Total Depreciation and Amortization (D&A)
0.41 0.25 0.02 0.00 0.00
Debt-free, Cash-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments
- - - - -
Adjusted Basic Earnings per Share
$0.00 ($2.41) ($1.07) $2.75 ($22.61)
Adjusted Weighted Average Basic Shares Outstanding
0.00 7.50M 12.29M 1.04M 1.76M
Adjusted Diluted Earnings per Share
$0.00 ($2.41) ($1.07) $2.75 ($22.61)
Adjusted Weighted Average Diluted Shares Outstanding
0.00 7.50M 12.29M 1.06M 1.76M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
0.00 8.58M 18.96M 1.31M 8.97M
Normalized Net Operating Profit after Tax (NOPAT)
-5.80 -16 -9.98 -12 -28
Normalized NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin
0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios
- - - - -
EBIT to Interest Expense
-22.52 -63.04 -66.52 37.20 0.00
NOPAT to Interest Expense
-13.94 -58.02 -49.58 -219.18 0.00
EBIT Less CapEx to Interest Expense
-22.30 -63.04 -66.52 37.20 0.00
NOPAT Less CapEx to Interest Expense
-13.72 -58.03 -49.58 -219.18 0.00
Payout Ratios
- - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Promis Neurosciences

This table displays calculated financial ratios and metrics derived from Promis Neurosciences' official financial filings.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
DEI Shares Outstanding
18,961,116.00 18,961,116.00 29,885,452.00 32,689,190.00 32,689,190.00 32,689,190.00 51,806,497.00 53,811,110.00 8,967,693.00 8,967,693.00 8,967,693.00
DEI Adjusted Shares Outstanding
758,445.00 758,445.00 1,195,418.00 1,307,568.00 1,307,568.00 1,307,568.00 2,072,260.00 2,152,444.00 8,967,693.00 8,967,693.00 8,967,693.00
DEI Earnings Per Adjusted Shares Outstanding
-4.79 -3.46 7.76 -0.18 -5.62 -7.74 -5.59 -4.96 -0.92 -1.31 -0.91
Growth Metrics
- - - - - - - - - - -
Revenue Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth
27.62% -16.01% 505.96% 93.91% -106.50% -285.61% -224.84% -4,383.36% -12.20% -15.94% 29.52%
EBIT Growth
27.64% -15.95% 505.90% 93.94% -106.50% -285.61% -224.84% -4,383.36% -12.20% -15.94% 29.52%
NOPAT Growth
26.03% 6.42% -151.64% -54.92% -102.90% -275.30% -85.48% -79.46% -15.88% -20.44% 26.68%
Net Income Growth
26.70% -13.48% 492.94% 93.35% -102.14% -285.61% -224.84% -4,381.01% -12.20% -15.94% 29.52%
EPS Growth
67.24% 51.85% 263.16% 93.35% -102.14% -123.08% -177.42% -2,543.48% 76.09% 82.37% 84.99%
Operating Cash Flow Growth
-301.75% 29.94% -180.72% -131.89% 52.13% -156.18% -50.73% -6.50% -151.35% -169.45% 6.75%
Free Cash Flow Firm Growth
-259.40% -251.65% 297.87% -1,390.70% 9.47% 34.31% -265.05% 118.67% 78.89% -71.62% 38.99%
Invested Capital Growth
74.30% 66.25% 0.00% 135.64% 143.81% -49.18% 56.32% -334.17% -391.38% 17.49% 62.44%
Revenue Q/Q Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth
9.05% 26.27% 453.55% -102.57% -2,984.67% -37.69% -14.46% 7.78% 22.80% -42.27% 30.42%
EBIT Q/Q Growth
9.46% 26.27% 453.55% -102.57% -2,984.67% -37.69% -14.46% 7.78% 22.80% -42.27% 30.42%
NOPAT Q/Q Growth
5.11% 26.19% -133.45% 5.25% -24.28% -36.52% -15.37% 8.33% 19.75% -41.89% 29.76%
Net Income Q/Q Growth
-1.53% 27.82% 453.55% -102.57% -2,984.67% -37.69% -14.46% 7.82% 22.76% -42.27% 30.42%
EPS Q/Q Growth
-533.33% 31.58% 338.46% -102.57% -2,984.67% -38.10% 17.24% -2,433.33% 79.28% -1.59% 30.47%
Operating Cash Flow Q/Q Growth
-173.84% 85.38% -343.41% -30.64% 43.47% 21.77% -160.90% 7.69% -33.42% 16.14% 9.71%
Free Cash Flow Firm Q/Q Growth
-786.86% 13.28% 217.67% -264.71% 46.14% 37.07% -195.64% 118.63% -160.89% -411.67% -5.10%
Invested Capital Q/Q Growth
72.38% -34.65% -332.96% 122.13% -66.04% -558.47% -26.78% -18.64% 57.75% -29.82% 42.29%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 99.95% 100.00% 100.00% 100.00%
Interest Burden Percent
102.16% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)
389.65% 225.81% -7.75% 27.46% -19.56% 633.71% -355.80% -521.61% -115.73% -172.30% -152.35%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% 0.00% -912.42% -1,671.13% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)
389.65% 225.81% -7.75% 27.46% -19.56% 633.71% -355.80% -521.61% -115.73% -172.30% -152.35%
Return on Equity Simple (ROE_SIMPLE)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
-2.57 -1.90 -4.43 -4.20 -5.22 -7.13 -8.23 -7.54 -6.05 -8.59 -6.03
NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)
-36.03% -63.53% 127.13% 30.54% -38.91% -107.32% -18.13% -32.18% -6.07% -10.84% -7.16%
Return On Investment Capital (ROIC_SIMPLE)
-3,338.12% 83.42% -60.97% -25.48% -55.13% 1,863.48% -89.53% 599.12% -9.97% -17.38% -14.44%
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)
-3.56 -2.62 9.28 -0.24 -7.35 -10 -12 -11 -8.24 -12 -8.16
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-3.56 -2.62 9.28 -0.24 -7.35 -10 -12 -11 -8.24 -12 -8.16
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
212.54 0.00 5.14 1.88 2.40 0.00 2.40 0.00 1.88 2.39 2.33
Price to Tangible Book Value (P/TBV)
212.54 0.00 5.14 1.88 2.40 0.00 2.40 0.00 1.88 2.39 2.33
Price to Revenue (P/Rev)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)
0.00 0.00 0.00 11.15 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 8.97% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00 5.58 13.35 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 6.18 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 6.18 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 3.94 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage
0.97 0.21 -2.97 -1.28 -1.14 2.09 -2.25 -1.28 -1.03 -1.18 -1.17
Leverage Ratio
-1.31 -0.27 3.37 1.61 1.80 -4.11 2.79 1.84 1.15 1.35 1.35
Compound Leverage Factor
-1.34 -0.27 3.37 1.61 1.80 -4.11 2.79 1.84 1.15 1.35 1.35
Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score
-38.48 -102.06 -1.55 1.98 -7.72 -18.51 -8.00 -23.04 7.98 6.36 6.60
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
1.34 0.44 9.30 8.52 3.36 0.97 1.76 0.88 9.92 7.85 8.83
Quick Ratio
0.96 0.32 8.19 6.01 2.07 0.46 1.26 0.59 9.65 7.41 8.26
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-9.66 -8.38 9.86 -16 -8.75 -5.51 -16 3.03 -1.85 -9.45 -9.93
Operating Cash Flow to CapEx
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense
-125.87 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense
-134.05 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
-134.05 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
-2.45 -3.30 -14 3.16 1.07 -4.93 -6.24 -7.41 -3.13 -4.06 -2.35
Invested Capital Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital
7.09 6.48 -14 12 3.53 -1.62 8.05 -11 -4.20 0.86 3.90
Enterprise Value (EV)
14 27 16 18 14 11 6.59 8.54 50 65 53
Market Capitalization
16 28 37 31 23 16 22 15 114 118 97
Book Value per Share
$0.01 ($0.12) $0.24 $0.50 $0.29 ($0.01) $0.18 ($0.02) $6.77 $5.51 $4.66
Tangible Book Value per Share
$0.01 ($0.12) $0.24 $0.50 $0.29 ($0.01) $0.18 ($0.02) $6.77 $5.51 $4.66
Total Capital
0.08 -2.28 7.27 16 9.47 -0.38 9.19 -1.26 61 49 42
Total Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt
-2.53 -1.02 -22 -13 -8.40 -4.54 -15 -6.15 -64 -53 -44
Capital Expenditures (CapEx)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-1.63 -2.79 0.31 3.37 1.19 -4.86 -6.19 -7.38 -4.85 -3.99 -2.29
Debt-free Net Working Capital (DFNWC)
0.90 -1.76 22 17 9.59 -0.31 9.25 -1.23 59 49 42
Net Working Capital (NWC)
0.90 -1.76 22 17 9.59 -0.31 9.25 -1.23 59 49 42
Net Nonoperating Expense (NNE)
1.06 0.72 -14 -3.96 2.13 2.99 3.35 3.13 2.19 3.14 2.13
Net Nonoperating Obligations (NNO)
-2.53 -1.02 -22 -13 -8.40 -4.54 -15 -6.15 -64 -53 -44
Total Depreciation and Amortization (D&A)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
($0.19) ($0.13) $0.31 ($5.75) ($5.25) ($0.29) ($0.24) ($6.08) ($1.26) ($1.28) ($0.89)
Adjusted Weighted Average Basic Shares Outstanding
19.53M 19.77M 30.02M 41.47K 1.39M 34.85M 48.83M 1.76M 6.53M 9.14M 9.14M
Adjusted Diluted Earnings per Share
($0.19) ($0.13) $0.31 ($5.75) ($5.25) ($0.29) ($0.24) ($6.08) ($1.26) ($1.28) ($0.89)
Adjusted Weighted Average Diluted Shares Outstanding
19.53M 19.77M 30.07M 42.34K 1.39M 34.85M 48.83M 1.76M 6.53M 9.14M 9.14M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 ($5.75) $0.00 $0.00 $0.00 ($6.08) $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
18.96M 29.89M 32.69M 1.31M 1.31M 51.81M 53.81M 8.97M 8.97M 8.97M 9.00M
Normalized Net Operating Profit after Tax (NOPAT)
-2.57 -1.90 -3.10 -4.20 -5.22 -7.13 -8.23 -7.54 -6.05 -8.59 -6.03
Normalized NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
-46.35 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense
-33.52 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
-46.35 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
-33.52 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

ProMIS Neurosciences (NASDAQ: PMN) remains a development-stage biotechnology company with no reported revenue. Total revenue was $0 in each of the provided quarters, so the company continues to depend on financing and its cash reserves to fund research and administrative activities.

  • Liquidity is substantially stronger than a year ago. Cash and equivalents increased to $53.4 million at June 30, 2026, compared with $4.5 million at June 30, 2025. Including $33,753 of short-term investments, PMN had approximately $53.4 million of readily available funds.
  • The balance sheet is now in a net asset position. Total equity was $49.4 million at the end of Q2 2026, versus negative equity of $382,578 at June 30, 2025. Total assets of $56.7 million also exceeded total liabilities of $7.3 million by a wide margin.
  • Current liquidity remains adequate relative to near-term liabilities. PMN reported $56.7 million of current assets and $7.2 million of current liabilities in Q2 2026, implying a current ratio of roughly 7.9.
  • Operating cash burn improved sequentially. Net cash used in operating activities declined to $10.4 million in Q2 2026 from $12.4 million in Q1 2026. The Q2 burn was also better than the $12.4 million used in Q2 2025.
  • Other income partially offset operating losses. Net other income rose to $536,743 in Q2 2026 from $400,523 in Q1, helping reduce the quarterly net loss relative to the operating loss.
  • Research spending remains the primary use of capital. Research and development expense was $9.5 million in Q2 2026, representing about 78% of total operating expenses. This spending may support pipeline development, but its investment value depends on future clinical and commercial progress that is not reflected in current revenue.
  • Cash runway appears meaningful but is difficult to estimate precisely. Q2 operating cash burn of $10.4 million would equate to roughly five quarters of cash on hand before considering changes in spending, financing, clinical milestones or working capital.
  • PMN continues to generate no operating revenue. With no revenue and a gross profit of zero in every provided income statement, the company has not yet demonstrated a recurring source of funds from product sales or licensing operations.
  • Net losses remain substantial and have worsened from earlier periods. The Q2 2026 net loss was $11.7 million, compared with $8.2 million in Q1 2026 and $10.1 million in the restated Q2 2025 period. Retained earnings stood at a deficit of $150.4 million at June 30, 2026.
  • Capital raises have materially increased dilution risk. PMN received $70.1 million from issuing common equity in Q1 2026, while weighted-average basic shares rose to 9.1 million in Q2 from 6.5 million in Q1 and 1.4 million in Q4 2025. Future funding needs could require additional equity issuance and further dilute existing shareholders.

Overall, PMN’s financial position has improved sharply because of equity financing, and its cash balance currently provides more flexibility than it had in 2024 and early 2025. However, the company remains dependent on external capital, has no reported revenue, and continues to consume roughly $10 million or more in cash each quarter. Investors should closely monitor operating cash burn, clinical progress, and the potential for additional share issuance.

11/22/26 12:49 PM ETAI Generated. May Contain Errors.

Promis Neurosciences Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Promis Neurosciences' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Promis Neurosciences' net income appears to be on a downward trend, with a most recent value of -$39.72 million in 2025, falling from -$9.79 million in 2021. The previous period was $2.78 million in 2024. View Promis Neurosciences' forecast to see where analysts expect Promis Neurosciences to go next.

Promis Neurosciences' total operating income in 2025 was -$40.17 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $40.17 million

Over the last 4 years, Promis Neurosciences' total revenue changed from $0.00 in 2021 to $0.00 in 2025, a change of 0.0%.

In the past 10 quarters, Promis Neurosciences' cash and equivalents has ranged from $992.46 thousand in Q2 2024 to $63.81 million in Q1 2026, and is currently $44.07 million as of their latest financial filing in Q3 2026.

Promis Neurosciences had total debt of $0.00 at the end of 2025, compared with none in 2024, and a 100.0% decrease since 2021.

Over the last 4 years, Promis Neurosciences' book value per share changed from 0.98 in 2021 to -0.02 in 2025.



Financial statements for NASDAQ:PMN last updated on 11/12/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners